All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


The Era of Targeted Therapy in Severe Asthma: Specialty Pharmacy Perspectives

Planning to attend Asembia’s 2018 Specialty Pharmacy Summit? Plan to attend for this CE Session:

Register for the Asembia’s 2018 Specialty Pharmacy Summit

Wednesday, May 2, 2018 - 7:00am - 8:30am PT
Encore Las Vegas, Room: Beethoven

Jointly provided by ProCE and the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) 

Activity Description

Pharmacists are confronted by the rapidly evolving landscape in severe asthma. Despite advances in asthma treatment, 5%-10% of patients having severe asthma fail to respond to conventional therapy, incurring hospitalizations, high economic burden, and associated morbidity and mortality. An improved understanding of the complex pathophysiology of severe asthma has facilitated the development of a targeted approach to treatment, including biologic therapies which shift available options into the domain of specialty pharmacy. It is important for pharmacists and other clinicians to stay current on new paradigms and approaches for managing severe asthma. This presentation will discuss the epidemiology and burden of severe asthma, the use of phenotypes and biomarkers, mechanisms of action evidence for new/emerging agents, and the pharmacist’s expanding role in asthma disease management and outcomes.

Learning Objectives

The target audience for this activity includes Specialty Pharmacy and Managed Care Pharmacy Professionals. After completing this activity, participants should be able to:

  • Discuss challenges associated with identifying and managing patients with severe asthma
  • Recognize the different asthma phenotypes through biomarkers and pathophysiological mechanisms
  • Examine the mechanisms of action, efficacy and safety profile of current and emerging targeted biologic therapies for severe asthma
  • Identify the specialty pharmacist’s role in patient intervention, disease management, and clinical outcomes tracking to personalize patient care in severe asthma


6:30 – 7:00 AM: Onsite Registration & Breakfast
7:00 – 8:30 AM: CE Activity


Tara N. Kelley, PharmD, CSP
Clinical Pharmacy Manager
Vanderbilt Specialty Pharmacy
Nashville, Tennessee

Dennis Williams, PharmD, BCPS, AE-C
Associate Professor
UNC Eshelman School of Pharmacy
Clinical Specialist
UNC Medical Center
Chapel Hill, North Carolina



ACPE LogoThis CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy Center for Specialty Pharmacy Education. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-083-L01-P has been assigned to this live application-based activity (initial release date 5-2-18). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation no later than June 1, 2018 to receive pharmacy CE credit. Statements of completion will be issued online and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Kelley has no relevant commercial and/or financial relationships to disclose. Dr. Williams has disclosed that his spouse is an employee and stockholder of GlaxoSmithKline. A portion of grant funds received by ProCE from AstraZeneca will be used to compensate the faculty for this presentation.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This activity is supported by an educational grant from AstraZeneca.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.